ITPA
Basic information
Region (hg38): 20:3208868-3223870
Previous symbols: [ "C20orf37" ]
Links
Phenotypes
GenCC
Source:
- developmental and epileptic encephalopathy, 35 (Strong), mode of inheritance: AR
- developmental and epileptic encephalopathy, 35 (Supportive), mode of inheritance: AR
- developmental and epileptic encephalopathy (Definitive), mode of inheritance: AR
- inosine triphosphatase deficiency (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Inosine triphosphatase deficiency | AR | Pharmacogenomic | Abnormal 6-mercaptopurine metabolism in ITPase-deficient patients may cause thiopurine drug toxicity | Biochemical; Neurologic | 1204209; 12384777; 17697198; 19214663; 19631656; 19682085; 26224535 |
ClinVar
This is a list of variants' phenotypes submitted to
- Inosine triphosphatase deficiency (11 variants)
- Developmental and epileptic encephalopathy, 35 (3 variants)
- not provided (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ITPA gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 55 | 60 | ||||
missense | 90 | 95 | ||||
nonsense | 7 | |||||
start loss | 1 | |||||
frameshift | 8 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 11 | |||||
splice region | 13 | 14 | 2 | 29 | ||
non coding | 47 | 15 | 64 | |||
Total | 12 | 15 | 96 | 105 | 19 |
Highest pathogenic variant AF is 0.0000131
Variants in ITPA
This is a list of pathogenic ClinVar variants found in the ITPA region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
20-3209336-G-A | Benign (May 12, 2021) | |||
20-3209393-C-G | Benign (May 13, 2021) | |||
20-3209439-C-T | Benign (May 26, 2021) | |||
20-3209552-A-G | Inosine triphosphatase deficiency | Uncertain significance (Jan 11, 2022) | ||
20-3209556-C-A | Inosine triphosphatase deficiency | Uncertain significance (Jul 15, 2021) | ||
20-3209557-G-T | Inosine triphosphatase deficiency | Likely benign (Jan 02, 2024) | ||
20-3209560-C-T | Inosine triphosphatase deficiency | Likely benign (Jul 26, 2022) | ||
20-3209564-T-C | Inosine triphosphatase deficiency | Likely benign (May 16, 2023) | ||
20-3209585-T-C | Inosine triphosphatase deficiency | Uncertain significance (Dec 11, 2023) | ||
20-3209592-C-T | Inborn genetic diseases | Uncertain significance (Mar 30, 2024) | ||
20-3209593-G-C | Inosine triphosphatase deficiency | Likely benign (Oct 09, 2020) | ||
20-3209598-ACGCCAAGAAGCTGGAGGAGGTG-A | Inosine triphosphatase deficiency | Likely pathogenic (Feb 13, 2020) | ||
20-3209599-C-T | Inosine triphosphatase deficiency | Likely benign (Mar 14, 2019) | ||
20-3209600-G-T | Inosine triphosphatase deficiency | Likely benign (Nov 27, 2023) | ||
20-3209608-GC-AA | Inosine triphosphatase deficiency | Uncertain significance (Sep 06, 2022) | ||
20-3209609-C-A | Inborn genetic diseases | Uncertain significance (Nov 09, 2021) | ||
20-3209617-G-A | Inosine triphosphatase deficiency | Uncertain significance (Jun 27, 2022) | ||
20-3209620-G-C | Developmental and epileptic encephalopathy, 35 | Uncertain significance (May 20, 2019) | ||
20-3209622-C-T | Inosine triphosphatase deficiency | Uncertain significance (Aug 01, 2022) | ||
20-3209625-G-T | Inosine triphosphatase deficiency | Uncertain significance (Jul 06, 2022) | ||
20-3209627-G-A | Inosine triphosphatase deficiency | Likely benign (Mar 23, 2022) | ||
20-3209627-G-C | Inosine triphosphatase deficiency | Likely benign (Dec 11, 2023) | ||
20-3209627-G-GGGT | Inosine triphosphatase deficiency | Likely benign (Jan 17, 2024) | ||
20-3209632-T-C | Inosine triphosphatase deficiency | Likely benign (Jul 03, 2023) | ||
20-3209633-T-G | Inosine triphosphatase deficiency | Likely benign (Dec 18, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ITPA | protein_coding | protein_coding | ENST00000380113 | 8 | 15003 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.01e-7 | 0.331 | 125706 | 0 | 42 | 125748 | 0.000167 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.123 | 111 | 115 | 0.968 | 0.00000672 | 1243 |
Missense in Polyphen | 37 | 50.72 | 0.7295 | 548 | ||
Synonymous | -0.453 | 52 | 48.0 | 1.08 | 0.00000302 | 373 |
Loss of Function | 0.578 | 12 | 14.4 | 0.836 | 8.34e-7 | 153 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000211 | 0.000210 |
Ashkenazi Jewish | 0.0000994 | 0.0000992 |
East Asian | 0.000272 | 0.000272 |
Finnish | 0.000419 | 0.000416 |
European (Non-Finnish) | 0.000168 | 0.000167 |
Middle Eastern | 0.000272 | 0.000272 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective monophosphate derivatives. The enzyme does not distinguish between the deoxy- and ribose forms. Probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal lesions. {ECO:0000255|HAMAP-Rule:MF_03148, ECO:0000269|PubMed:17090528}.;
- Disease
- DISEASE: Epileptic encephalopathy, early infantile, 35 (EIEE35) [MIM:616647]: A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. EIEE35 is characterized by onset of seizures in the first months of life associated with essentially no normal development. Many patients die in early childhood. {ECO:0000269|PubMed:26224535}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Drug metabolism - other enzymes - Homo sapiens (human);Purine metabolism - Homo sapiens (human);Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics;Purine Nucleoside Phosphorylase Deficiency;Mercaptopurine Action Pathway;Azathioprine Action Pathway;Pyrimidine Metabolism;Xanthine Dehydrogenase Deficiency (Xanthinuria);Adenylosuccinate Lyase Deficiency;AICA-Ribosiduria;Thioguanine Action Pathway;Adenine phosphoribosyltransferase deficiency (APRT);Mitochondrial DNA depletion syndrome;Myoadenylate deaminase deficiency;Purine Metabolism;UMP Synthase Deiciency (Orotic Aciduria);MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy);Molybdenum Cofactor Deficiency;Adenosine Deaminase Deficiency;Gout or Kelley-Seegmiller Syndrome;Lesch-Nyhan Syndrome (LNS);Xanthinuria type I;Xanthinuria type II;Beta Ureidopropionase Deficiency;Dihydropyrimidinase Deficiency;Nucleobase catabolism;Metabolism of nucleotides;Metabolism;Purine nucleotides nucleosides metabolism;Pyrimidine nucleotides nucleosides metabolism;Purine catabolism
(Consensus)
Recessive Scores
- pRec
- 0.469
Intolerance Scores
- loftool
- 0.304
- rvis_EVS
- 0.06
- rvis_percentile_EVS
- 58.53
Haploinsufficiency Scores
- pHI
- 0.0526
- hipred
- Y
- hipred_score
- 0.626
- ghis
- 0.473
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0873
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Itpa
- Phenotype
- hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; cellular phenotype; muscle phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);
Gene ontology
- Biological process
- ITP catabolic process;purine nucleotide catabolic process;nucleoside triphosphate catabolic process;deoxyribonucleoside triphosphate catabolic process;chromosome organization
- Cellular component
- cytosol
- Molecular function
- nucleotide binding;NADH pyrophosphatase activity;dITP diphosphatase activity;ITP diphosphatase activity;XTP diphosphatase activity;identical protein binding;metal ion binding;nucleoside-triphosphate diphosphatase activity